Non-classical HLA-G antigen and its role in the cancer progression

Cancer Investigation

Volumn 24, Issue 2, 2006, Pages 178-186

  Tripathi, Piyush ^a   Agrawal, Suraksha ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

HLA G; Immunosurvillance; KIR; Tumor

Indexed keywords

HLA G ANTIGEN;

CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER THERAPY; CELL VIABILITY; GENE EXPRESSION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MONITORING, IMMUNOLOGIC; NEOPLASMS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 33645012941     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500524579     Document Type: Review

References (76)

1. Paul, P.; Rouas-Freiss, N.; Khalil-Daher, I.; Moreau, P.; Riteau, B.; et al. HLA-G expression in melanoma, a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA. 1998, 95 (8), 4510-4515.
2. Agrawal, S.; Pandey, M.K. The potential role of HLA-G polymorphism in maternal tolerance to the developing fetus. J. Hemat. Stem Cell Res. 2003, 12 (6), 749-756.
3. Rouas-Freiss, N.; Moreau, P.; Menier, C.; Carosella, E. D. HLA-G in cancer, a way to turn off the immune system. Semin. Cancer Biol. 2003, 13 (5), 325-336.
4. Boon, T.; Cerottini, J.C.; Van den Eynde, B.; Van der Bruggen, P.; Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994, 12, 337-365.
5. de Vries, T.J.; Fourkour, A.; Wobbes, T.; Verkroost, G.; Ruiter, D.J.; van Muijen, G.N. Heterogeneous expression of immunotherapy candidate proteins gp100; MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997, 57 (15), 3223-3229.
6. Garrido, F.; Ruiz-Cabello, F.; Cabrera, T.; Perez-Villar, J.J.; Lopez-Botet, M.; Duggan-Keen, M.; Stern, P.L. Implications for immunosurvillance of altered HLA class I phenotypes in the tumors. Immunol. Today 1997, 18 (2), 89-95.
7. Hicklin, D.J.; Wang, Z.; Arienti, F.; Rivoltini, L.; Parmiani, G.; Ferrone, S. β-2 microglobulin mutations; HLA class I antigen loss; and tumor progression in melanoma. J. Clin. Invest. 1998, 101 (12), 2720-2729.
8. Ramal, L.M.; Maleno, I.; Cabrera, T.; Collado, A.; et al. Molecular strategies to define HLA haplotype loss in micro dissected tumor cells. Hum. Immunol. 2000, 61 (10), 1001-1012.
9. Korkolopoulou, P.; Kaklamanis, L.; Pezzella, F.; Harris, A.L.; Gatter, K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer 1996, 73 (2) 148-153.
10. Sanda, M.G.; Restifo, N.P.; Walsh, J.C.; Kawakami, Y.; Nelson, W.G.; et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 1995, 87 (4), 280-285.
11. Seliger, B.; Hohne, A.; Jung, D.; Kallfelz, M.; Knuth, A.; et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol. 1997, 25 (7), 608-614.
12. Soong, T.W.; Hui, K.M. Locus-specific transcriptional control of HLA genes. J. Immunol. 1992, 149 (6), 2008-2020.
13. Garrido, F.; Cabrera, T.; Lopez-Nevot, M.A.; Ruiz-Cabello, F. HLA class I antigens in human tumors. Adv. Cancer Res. 1995, 67, 155-195.
14. Marincola, F.M.; Jaffee, E.M.; Hicklin, D.J.; Ferrone, S. Escape of human solid tumors from T-cell recognition, molecular mechanisms and functional significance. Adv. Immunol. 2000, 74, 181-273.
15. Stern, P.L.; Rinke de Wit, T.F. The role of MHC class I expression in developmental tumours. Semin. Cancer Biol. 1991, 2 (1), 11-16.
16. Cabrera, T.; Angustias Fernandez, M.; Sierra, A.; Garrido, A.; Herruzo, A.; et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 1996, 50 (2), 127-134.
17. Bontkes, H.J.; Walboomers, J.M.; Meijer, C.J.; Helmerhorst, T.J.; Stern, P.L. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998, 351 (9097), 187-188.
18. Ljunggren, H.G.; Karre, K. In search of the 'missing self', MHC molecules and NK cell recognition. Immunol. Today 1990, 11 (7), 237-244.
19. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting, from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3 (11), 991-998.
20. Girardi, M.; Oppenheim, D.E.; Steele, C.R.; Lewis, J.M.; Glusac, E.; et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294 (5542), 605-609.
21. Street, S.E.; Trapani, J.A.; MacGregor, D.; Smyth, M.J. Suppression of lymphoma and epithelial malignancies affected by interferon gamma. J. Exp. Med. 2002, 196 (1), 129-134.
22. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFN gamma and lymphocytes prevent primary tumors development and shape tumors immunogenicity. Nature 2001, 410 (6832), 1107-1111.
23. Takeda, K.; Smyth, M.J.; Cretney, E.; Hayakawa, Y.; Kayagaki, N.; Yagita, H.; Okumura, K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 2002, 195 (2), 161-169.
24. Gerosa, F.; Baldani-Guerra, B.; Nisii, C.; Marchesini, V.; Carra, G.; Trinchieri, G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195 (3), 327-333.
25. Apte, R.S.; Mayhew, E.; Niederkorn, J.Y. Local inhibition of natural killer cell activity promotes the progressive growth of intra ocular tumors. Invest. Ophthalmol. Vis. Sci. 1997, 38 (6), 1277-1282.
26. Oyama, T.; Ran, S.; Ishida, T.; Nadaf, S.; Kerr, L.; et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160 (3), 1224-1232.
27. Girolomoni, G.; Ricciardi-Castagnoli, P. Dendritic cells hold promise for immunotherapy. Immunol. Today 1997, 18 (3), 102-104.
28. Zeidler, R.; Eissner, G.; Meissner, P.; Uebel, S.; Tampe, R.; et al. Down regulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997, 90 (6), 2390-2397.
29. Van den Eynde, B.; Gaugler, B.; van der Bruggen, P.; Coulie, P.; Brichard, V.; Boon, T. Human tumour antigens recognized by T-cells, Perspectives for new cancer vaccines. Biochem. Soc. Trans. 1995, 23 (3), 681-686.
30. Zaks, T.Z.; Chappell, D.B.; Rosenberg, S.A.; Restifo, N.P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor, selective rescue by caspase inhibition. J. Immunol. 1999, 162 (6), 3273-3279.
31. Urosevic, M.; Kurrer, M.O.; Kamarashev, J.; Mueller, B.; Weder, W.; et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology; human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 2001, 159 (3), 817-824.
32. Fukushima, Y.; Oshika, Y.; Nakamura, M.; Tokunaga, T.; Hatanaka, H.; et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med. 1998, 2 (3), 349-351.
33. Wagner, S.N.; Rebmann, V.; Willers, C.P.; Grosse-Wilde, H.; Goos, M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000, 356 (9225), 220-221.
34. Urosevic, M.; Willers, J.; Mueller, B.; Kempf, W.; Burg, G.; Dummer, R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002, 99 (2), 609-617.
35. Lefebvre, S.; Antoine, M.; Uzan, S.; McMaster, M.; Dausset, J.; Carosella, E.D.; Paul, P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 2002, 196 (3), 266-274.
36. Ibrahim, E.C.; Guerra, N.; Lacombe, M.J.; Angevin, E.; Chouaib, S.; Carosella, E.D.; Caignard, A.; Paul, P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 2001, 61 (18), 6838-6845.
37. Wiendl, H.; Mitsdoerffer, M.; Hofmeister, V.; Wischhusen, J.; Bornemann, A.; Meyermann, R.; Weiss, E.H., Melms, A.; Weller, M. A functional role of HLA-G expression in human gliomas, an alternative strategy of immune escape. J. Immunol. 2002, 168 (9), 4772-4780.
38. Carosella, E.D.; Paul, P.; Moreau, P.; Rouas-Freiss, N. HLA-G and -E,fundamental and physiological aspects. Immunol. Today 2000, 21 (11), 532-534.
39. Maier, S.; Geraghty, D.E.; Weiss, E.H. Expression and regulation of HLA-G in human glioma cell lines. Transplant. Proc. 1999, 31 (4), 1849-1853.
40. Paul, P.; Cabestre, F.A.; Le Gal, F.A.; Khalil Daher, I.; Le Danff, C.; et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999, 59 (8), 1954-1960.
41. Hamai, Y.; Fujii, T.; Yamashita, T.; Miki, A.; Hyodo, H.; et al. The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 toward them. Am. J. Reprod. Immunol. 1999, 41 (2), 153-158.
42. Pangault, C.; Amiot, L.; Caulet-Maugendre, S.; Brasseur, F.; Burtin, F.; et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens 1999, 53 (4 Pt. 1), 335-346.
43. Adrian Cabestre, F.; Moreau, P.; Riteau, B.; Ibrahim, E.C.; Le Danff, C.; et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J. Reprod. Immunol. 1999, 43 (2), 183-193.
44. Riteau, B.; Faure, F.; Menier, C.; Viel, S.; Carosella, E.D.; et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol. 2003, 64 (11), 1064-1072.
45. Kirszenbaum, M.; Djoulah, S.; Hors, J.; Prost, S.; Dausset, J.; Carosella, E.D. Polymorphism of HLA-G gene and protein. J. Reprod. Immunol. 1999, 43 (2), 105-109.
46. Ishitani, A.; Geraghty, D.E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. USA. 1992, 89 (9), 3947-3951.
47. Paul, P.; Cabestre, F.A.; Ibrahim, E.C.; Lefebvre, S.; Khalil-Daher, I.; et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5; -G6; and -G7 transcripts in human transfected cells. Hum. Immunol. 2000, 61 (11) 1138-1149.
48. Sanders, SK.; Giblin, P.A.; Kavathas, P. Cell-cell adhesion mediated by CD8 and human histocompatibility leukocyte antigen G; a nonclassical major histocompatibility complex class 1 molecule on cytotrophoblasts. J. Exp. Med. 1991, 174 (3), 737-740.
49. Lee, N.; Malacko, A.R.; Ishitani, A.; Chen, M.C.; Bajorath, J.; et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 1995, 3 (5), 591-600.
50. Rouas-Freiss, N.; Moreau, P.; Menier, C.; Carosella. E/D. HLA-G in cancer, a way to turn off the immune system. Semin. Cancer. Biol. 2003, 13 (5), 325-336.
51. Aractingi, S.; Kanitakis, J.; Euvrard, S.; Le Danff, C.; Carosella, E.D. Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients. Int. J. Cancer. 2003, 106 (2), 232-235.
52. Rajagopalan, S.; Long, E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 1999, 189 (7), 1093-1100.
53. Ponte, M.; Cantoni, C.; Biassoni, R.; Tradori-Cappai, A.; Bentivoglio, G.; et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy, decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49; an HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA. 1999, 96 (10), 5674-5679.
54. Navarro, F.; Llano, M.; Bellon, T.; Colonna, M.; Geraghty, D.E.; Lopez-Botet, M. The ILT2 (LIR1) and CD94/NKG2A NK cellreceptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur. J. Immunol. 1999, 29 (1), 277-283.
55. Colonna, M.; Samaridis, J.; Cella, M.; Angmanm, L.; Allenm, R.L.; et al. Cutting edge: human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 1998, 160 (7), 3096-3100.
56. Borrego, F.; Ulbrecht, M.; Weiss, E.H.; Coligan, J.E.; Brooks, A.G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 1998, 187 (5), 813-818.
57. Riteau, B.; Menier, C.; Khalil-Daher, I.; Martinozzi, S.; Pla, M.; et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int. Immunol. 2001, 13 (2), 193-201.
58. Menier, C.; Riteau, B.; Carosella, E.D.; Rouas-Freiss, N. The MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int. J. Cancer. 2002, 100 (1), 63-70.
59. Vyas, Y.M.; Mehta, K.M.; Morgan, M.; Maniar, H.; Butros, L.; et al. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated non-cytolytic and cytolytic interactions. J. Immunol. 2001, 167 (8), 4358-4367.
60. Forte, P.; Pazmany, L.; Matter-Reissmann, U.B.; Stussi, G.; Schneider, M.K.; Seebach, J.D. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J. Immunol. 2001, 167 (10), 6002-6008.
61. Dorling, A.; Monk, N.; Lechler, R. HLA-G inhibits the transendothelial cell migration of human NK cells, a strategy for inhibiting xenograft rejection. Transplant. Proc. 2000, 32 (5), 938.
62. Fournel, S.; Aguerre-Girr, M.; Huc, X.; Lenfant, F.; Alam, A.; Toubert, A.; et al. Cutting edge, soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol. 2000, 164 (12), 6100-6104.
63. Bainbridge, D.R.; Ellis, S.A.; Sargent, I.L. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J. Repord. Immunol. 2000, 48 (1), 17-26.
64. Gobin, S.J.; van den Elsen, P.J. Transcriptional regulation of the MHC class Ib genes HLA-E; HLA-F; and HLA-G. Hum. Immunol. 2000, 61 (11), 1102-1107.
65. Gobin, S.J.; Keijsers, V.; van Zutphen, M.; van den Elsen, P.J. The role of enhancer A in the locus-specific trans activation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J. Immunol. 1998, 161 (5), 2276-2283.
66. Lefebvre, S.; Berrih-Aknin, S.; Adrian, F.; Moreau, P.; Poea, S.; et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J. Biol. Chem. 2001, 276 (9), 6133-6139.
67. Ibrahim, E.C.; Morange, M.; Dausset, J.; Carosella, E.D.; Paul, P. Heat shock and arsenite induce expression of the non classical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 2000, 5 (3), 207-218.
68. Chang, C.C.; Ferrone, S. HLA-G in melanoma, can the current controversies be solved? Semin. Cancer Biol. 2003, 13 (5), 361-369.
69. Spencer, J.V.; Lockridge, K.M.; Barry, P.A.; Lin, G.; Tsang, M.; Penfold, M.E.; Schall, T.J. Potent immunosuppressive activities of cytomegalovirus encoded interleukin-10. J. Virol. 2002, 76 (3), 1285-1292.
70. Kanai, T.; Fujii, T.; Unno, N.; Yamashita, T.; Hyodo, H.; et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the deciduas versus peripheral blood. Am. J. Reprod. Immunol. 2001, 45 (2), 94-99.
71. Frumento, G.; Franchello, S.; Palmisano, G.L.; Nicotra, M.R.; Giacomini, P.; et al. Melanomas and melanoma cell lines do not express HLA-G; and the expression cannot be induced by gamma IFN treatment. Tissue Antigens 2000, 56 (1), 30-37.
72. Esteller, M.; Fraga, M.F.; Paz, M.F.; Campo, E.; Colomer, D.; et al. Cancer epigenetics and methylation. Science 2002, 297 (5588), 1807-1808.
73. Guillaudeux, T.; Rodriguez, A.M.; Girr, M.; Mallet, V.; Ellis, S.A.; et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J. Immunol. 1995, 154 (7), 3283-3299.
74. Moreau, P.; Mouillot, G.; Rousseau, P.; Marcou, C.; Dausset, J.; Carosella, E.D. HLA-G gene repression is reversed by demethylation. Proc. Natl. Acad. Sci. USA. 2003, 100 (3), 1191-1196.
75. Brown, R.; Strathdee, G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 2002, 8 (Suppl. 4), S43-S48.
76. Christman J.K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation, mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21 (35), 5483-5495.